Albireo Pharma, Inc.
ALBONASDAQHealthcare
$44.15
+$0.00(+0.00%)
Market Cap$915887335
P/E Ratio—
52W High$45.23
52W Low$16.02
Albireo Pharma, Inc. (ALBO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALBO · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2023Report Date: Mar 7, 2023EPS Actual
-$0.57
Est. -$1.80 · +68.3%
Revenue
—
Est. $0.01B
Fiscal Period
Q1 FY2023
FY ends December
Report Date
Mar 7, 2023
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
ALBO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2023 | May 15, 2023 | -$1.97 | — | — | — | $0.01B | — |
| ▲ Q1 FY2023 | Mar 7, 2023 | -$1.80 | -$0.57 | +68.3% | — | $0.01B | — |
| ▼ Q4 FY2022 | Nov 8, 2022 | -$1.06 | -$1.92 | -81.1% | $0.01B | — | — |
| ▼ Q3 FY2022 | Aug 15, 2022 | -$1.65 | -$2.04 | -23.6% | $0.01B | — | — |
| ▼ Q2 FY2022 | May 16, 2022 | -$1.85 | -$2.19 | -18.4% | $0.01B | $0.01B | +22.5% |
| ▲ Q1 FY2022 | Mar 1, 2022 | -$1.35 | -$0.57 | +57.8% | $0.03B | $0.01B | +316.9% |
| ▲ Q4 FY2021 | Nov 4, 2021 | -$0.38 | $2.90 | +863.2% | $0.00B | $0.00B | +4.7% |
| ▲ Q3 FY2021 | Aug 5, 2021 | -$1.97 | -$1.90 | +3.5% | $0.00B | $0.00B | +0.0% |
Q2 FY2023
May 15, 2023
EPS Actual
—
EPS Est.
-$1.97
EPS Surpr.
—
Revenue
—
Q1 FY2023
Mar 7, 2023Beat
EPS Actual
-$0.57
EPS Est.
-$1.80
EPS Surpr.
+68.3%
Revenue
—
Q4 FY2022
Nov 8, 2022Miss
EPS Actual
-$1.92
EPS Est.
-$1.06
EPS Surpr.
-81.1%
Revenue
$0.01B
Q3 FY2022
Aug 15, 2022Miss
EPS Actual
-$2.04
EPS Est.
-$1.65
EPS Surpr.
-23.6%
Revenue
$0.01B
Q2 FY2022
May 16, 2022Miss
EPS Actual
-$2.19
EPS Est.
-$1.85
EPS Surpr.
-18.4%
Revenue
$0.01B
Q1 FY2022
Mar 1, 2022Beat
EPS Actual
-$0.57
EPS Est.
-$1.35
EPS Surpr.
+57.8%
Revenue
$0.03B
Q4 FY2021
Nov 4, 2021Beat
EPS Actual
$2.90
EPS Est.
-$0.38
EPS Surpr.
+863.2%
Revenue
$0.00B
Q3 FY2021
Aug 5, 2021Beat
EPS Actual
-$1.90
EPS Est.
-$1.97
EPS Surpr.
+3.5%
Revenue
$0.00B
No analyst estimates available for ALBO.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2023 | Mar 7, 2023 | +68.3% | $44.15 | — | — |
| ▼ Q4 FY2022 | Nov 8, 2022 | -81.1% | $22.38 | $22.15 | -1.03% |
| ▼ Q3 FY2022 | Aug 15, 2022 | -23.6% | $23.85 | $24.93 | +4.53% |
| ▼ Q2 FY2022 | May 16, 2022 | -18.4% | $28.00 | $28.04 | +0.14% |
| ▲ Q1 FY2022 | Mar 1, 2022 | +57.8% | $33.34 | $27.57 | -17.31% |
| ▲ Q4 FY2021 | Nov 4, 2021 | +863.2% | $31.29 | $29.51 | -5.69% |
| ▲ Q3 FY2021 | Aug 5, 2021 | +3.5% | $27.54 | $30.02 | +9.01% |
| ▼ Q2 FY2021 | May 6, 2021 | -29.4% | $30.40 | $30.19 | -0.69% |
Q1 FY2023—
Report Date
Mar 7, 2023
EPS Beat/Miss
+68.3%
Price Before
$44.15
Price After
—
Q4 FY2022-1.03%
Report Date
Nov 8, 2022
EPS Beat/Miss
-81.1%
Price Before
$22.38
Price After
$22.15
Q3 FY2022+4.53%
Report Date
Aug 15, 2022
EPS Beat/Miss
-23.6%
Price Before
$23.85
Price After
$24.93
Q2 FY2022+0.14%
Report Date
May 16, 2022
EPS Beat/Miss
-18.4%
Price Before
$28.00
Price After
$28.04
Q1 FY2022-17.31%
Report Date
Mar 1, 2022
EPS Beat/Miss
+57.8%
Price Before
$33.34
Price After
$27.57
Q4 FY2021-5.69%
Report Date
Nov 4, 2021
EPS Beat/Miss
+863.2%
Price Before
$31.29
Price After
$29.51
Q3 FY2021+9.01%
Report Date
Aug 5, 2021
EPS Beat/Miss
+3.5%
Price Before
$27.54
Price After
$30.02
Q2 FY2021-0.69%
Report Date
May 6, 2021
EPS Beat/Miss
-29.4%
Price Before
$30.40
Price After
$30.19
Avg Beat Reaction-4.66%
Avg Miss Reaction+0.74%
Beat Rate4 / 8 quarters
Largest Move-17.31% (Q1 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALBO ends December
Albireo Pharma, Inc. (ALBO) most recently reported earnings on March 7, 2023 for Q1 FY2023, posting EPS of $-0.57 — beating the analyst consensus of $-1.80 by +68.3%. The next ALBO earnings date is expected around September 1, 2026.
Each quarter, investors track ALBO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALBO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALBO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALBO earnings · 5 questionsAlbireo Pharma, Inc.'s next earnings report is expected around September 1, 2026. ALBO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALBO historically reports after market close (AMC).
ALBO earnings datewhen is ALBO earningsALBO next earnings datewhen does ALBO report earningsALBO earnings calendar
▸ Source: FMP · Albireo Pharma, Inc. SEC filings · US GAAP · Albireo Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026